Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5 | P09917 | 6/20 | 0.45 |
| ▸ | PTGS2 | P35354 | 5/20 | 0.45 |
| ▸ | GLS2 | Q9UI32 | 1/20 | 0.45 |
| ▸ | STAT3 | P40763 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 2/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.38 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11236411 | 0.84 | ALOX5 (0.63) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL11407532 | 0.84 | ALOX5 (0.63) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL11404872 | 0.82 | ALOX5 (0.45) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL13174362 | 0.75 | STAT3 (0.47) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL5080244 | 0.75 | STAT3 (0.47) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL17817858 | 0.73 | STAT3 (0.81) | STAT3BACE1ACHEPTPN1 | |
| SCHEMBL18104304 | 0.72 | ALOX5 (0.38) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL17817859 | 0.72 | ACHE (0.67) | ALOX5PTGS2GLS2STAT3BACE1 | |
| SCHEMBL11023972 | 0.71 | ALOX5 (0.71) | ALOX5PTGS2GLS2BACE1ACHE | |
| SCHEMBL10336977 | 0.71 | ALOX5 (0.71) | ALOX5PTGS2GLS2BACE1ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MITOTECH SA (LU) | 2016-09-29 | — | — | US | disclosed |
| EP-3030267-A2 | MITOCHONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | Mitotech SA (LU) | 2016-06-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160279154-A1 | MITOCONDRIALLY-TARGETED TIMOQUINONES AND TOLUQUINONES | MT-ND2, MT-ND5, MT-ND1 | ALOX5 1398/4885PTGS2 973/4885GLS2 97/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.